ClinicalTrials.gg
CompletedNCT04660643SURMOUNT-4Updated May 22, 2024Results posted

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 70 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
783
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
8th of 104
783 · median 69
Started
2021
with 5 others
Phase 3
26 of 104
7 open now
Registered
5th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 8th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Metabolism and Nutrition Disorder
  • Prediabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
  • History of at least one unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus
  • Change in body weight greater than 5 kg within 3 months prior to starting study
  • Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
  • History of pancreatitis
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Any lifetime history of a suicide attempt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
783 participants (actual)

Study arms

  • Experimental
    Tirzepatide (lead-in)

    Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.

    Drug: Tirzepatide

  • Experimental
    Tirzepatide MTD

    Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received weekly doses of placebo SC for 52 weeks.

    Other: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • OtherPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change From Randomization in Body Weight at Week 88

    Least square (LS) mean was analysed by mixed model repeated measures (MMRM) model with randomization + analysis country + sex + interactive web response system (IWRS) MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

Secondary outcomes

  1. Percent Change From Randomization in Body Weight at Week 64

    LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 64

  2. Change From Randomization in Body Weight

    LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  3. Change From Randomization in Waist Circumference

    LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  4. Change From Randomization in Body Mass Index (BMI)

    LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  5. Change From Randomization in Fasting Glucose

    LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  6. Change From Randomization in Hemoglobin A1c (HbA1c)

    LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  7. Percent Change From Randomization in Fasting Insulin

    LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  8. Percent Change From Randomization in Lipid Parameters (Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Very Low Density Lipoprotein (VLDL) Cholesterol, Triglycerides, Free Fatty Acids (FFA))

    LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  9. Change From Randomization in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)

    LS mean change was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  10. Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score

    The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  11. Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score

    The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

    Time frame: Randomization (Week 36), Week 88

  12. Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period

    Percentage of Participants Who Maintain at least 80% of the Body Weight Lost During the Open-Label Lead-In Period was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.

    Time frame: Week 88

  13. Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline

    Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction from baseline was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.

    Time frame: Baseline (Week 0) to Week 88

  14. Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period

    Time to first occurrence of participants returning to \>95% baseline weight for those who lost ≥5% during the open-label lead-in period.

    Time frame: Randomization (Week 36) to Week 88

  15. Change From Baseline in BMI

    LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + BMI at randomization (kg/m\^2) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  16. Change From Baseline in Body Weight

    LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  17. Percent Change From Baseline in Body Weight

    LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  18. Change From Baseline in Waist Circumference

    LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  19. Change From Baseline in Fasting Glucose

    LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  20. Change From Baseline in HbA1c

    LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  21. Percent Change From Baseline in Fasting Insulin

    LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  22. Percent Change From Baseline in Lipid Parameters (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides, FFAs)

    LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  23. Change From Baseline in SBP, DBP

    LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  24. Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score

    The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

  25. Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score

    The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with baseline + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

    Time frame: Baseline (Week 0), Week 88

07

Results

Posted May 22, 2024

Participant flow

Open-label Lead-in Period (Week 0 - 36)
Participant flow — Open-label Lead-in Period (Week 0 - 36)
MilestoneTirzepatide (lead-in)PlaceboTirzepatide MTD
Started78300
Received at least 1 dose of study drug78200
Completed 36-weeks of treatment (i.e., reaching and tolerating the mtd at week 36)67000
Completed67100
Not completed11200
Withdrew: Adverse event5000
Withdrew: Death100
Withdrew: Lost to follow-up1400
Withdrew: Pregnancy100
Withdrew: Physician decision100
Withdrew: Protocol deviation1000
Withdrew: Withdrawal by subject3200
Withdrew: Covid-19100
Withdrew: Other - as reported by the investigator200
Double-blind Study Period (Week 36 - 92)
Participant flow — Double-blind Study Period (Week 36 - 92)
MilestoneTirzepatide (lead-in)PlaceboTirzepatide MTD
Started0335335
Received at least 1 dose of study drug0335335
Completed0290310
Not completed04525
Withdrew: Death011
Withdrew: Lost to follow-up0108
Withdrew: Pregnancy021
Withdrew: Withdrawal by subject02213
Withdrew: Protocol deviation012
Withdrew: Other - as reported by the investigator080
Withdrew: Perceived excessive weight loss010

Outcome measures

PrimaryPercent Change From Randomization in Body Weight at Week 88

Least square (LS) mean was analysed by mixed model repeated measures (MMRM) model with randomization + analysis country + sex + interactive web response system (IWRS) MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · percent change
Percent Change From Randomization in Body Weight at Week 88
percent changePlaceboTirzepatide MTD
Percent Change From Randomization in Body Weight at Week 8814.8 ± 0.53-6.7 ± 0.52
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -21.4 · 95% CI -22.9 to -20.0
SecondaryPercent Change From Randomization in Body Weight at Week 64

LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 64
Reported as:
Least squares mean · percent change
Percent Change From Randomization in Body Weight at Week 64
percent changePlaceboTirzepatide MTD
Percent Change From Randomization in Body Weight at Week 649.9 ± 0.38-6.0 ± 0.37
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -15.9 · 95% CI -17.0 to -14.9
SecondaryChange From Randomization in Body Weight

LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · kilogram (kg)
Change From Randomization in Body Weight
kilogram (kg)PlaceboTirzepatide MTD
Change From Randomization in Body Weight11.9 ± 0.43-5.7 ± 0.42
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -17.6 · 95% CI -18.8 to -16.4
SecondaryChange From Randomization in Waist Circumference

LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · centimetre (cm)
Change From Randomization in Waist Circumference
centimetre (cm)PlaceboTirzepatide MTD
Change From Randomization in Waist Circumference8.3 ± 0.44-4.6 ± 0.43
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -12.9 · 95% CI -14.1 to -11.7
SecondaryChange From Randomization in Body Mass Index (BMI)

LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · kilogram per square metre (kg/m^2)
Change From Randomization in Body Mass Index (BMI)
kilogram per square metre (kg/m^2)PlaceboTirzepatide MTD
Change From Randomization in Body Mass Index (BMI)4.3 ± 0.16-2.1 ± 0.15
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -6.4 · 95% CI -6.8 to -6.0
SecondaryChange From Randomization in Fasting Glucose

LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Randomization in Fasting Glucose
milligrams per deciliter (mg/dL)PlaceboTirzepatide MTD
Change From Randomization in Fasting Glucose7.74 ± 0.548-0.90 ± 0.528
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -8.64 · 95% CI -10.14 to -7.15
SecondaryChange From Randomization in Hemoglobin A1c (HbA1c)

LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · percentage of HbA1c
Change From Randomization in Hemoglobin A1c (HbA1c)
percentage of HbA1cPlaceboTirzepatide MTD
Change From Randomization in Hemoglobin A1c (HbA1c)0.25 ± 0.017-0.08 ± 0.017
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -0.33 · 95% CI -0.38 to -0.28
SecondaryPercent Change From Randomization in Fasting Insulin

LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · percent change
Percent Change From Randomization in Fasting Insulin
percent changePlaceboTirzepatide MTD
Percent Change From Randomization in Fasting Insulin23.3 ± 4.37-15.4 ± 2.88
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -31.4 · 95% CI -37.7 to -24.4
SecondaryPercent Change From Randomization in Lipid Parameters (Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Very Low Density Lipoprotein (VLDL) Cholesterol, Triglycerides, Free Fatty Acids (FFA))

LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · percent change
Percent Change From Randomization in Lipid Parameters (Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Very Low Density Lipoprotein (VLDL) Cholesterol, Triglycerides, Free Fatty Acids (FFA))
percent changePlaceboTirzepatide MTD
Total Cholesterol8.30 ± 0.9432.29 ± 0.852
LDL Cholesterol3.43 ± 1.368-3.36 ± 1.218
HDL Cholesterol14.6 ± 1.0618.3 ± 1.05
VLDL Cholesterol14.7 ± 2.32-7.8 ± 1.77
Triglycerides15.6 ± 2.39-8.2 ± 1.81
FFA-2.9 ± 2.98-13.4 ± 2.54
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -5.54 · 95% CI -7.76 to -3.28
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -6.57 · 95% CI -9.87 to -3.15
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = 0.014 · Ls mean difference: 3.2 · 95% CI 0.6 to 5.8
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -19.7 · 95% CI -24.0 to -15.1
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -20.6 · 95% CI -24.9 to -16
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = 0.008 · Ls mean difference: -10.8 · 95% CI -17.9 to -3.0
SecondaryChange From Randomization in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)

LS mean change was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · millimetre of mercury (mmHg)
Change From Randomization in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)
millimetre of mercury (mmHg)PlaceboTirzepatide MTD
SBP8.4 ± 0.642.1 ± 0.61
DBP3.2 ± 0.44-0.4 ± 0.42
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -6.4 · 95% CI -8.1 to -4.6
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -3.6 · 95% CI -4.8 to -2.4
SecondaryChange From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score

The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · T-score
Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score
T-scorePlaceboTirzepatide MTD
Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score-1.8 ± 0.320.8 ± 0.31
Statistical analysis
  • Placebo vs Tirzepatide MTD · ANCOVA · p = <.001 · Ls mean difference: 2.6 · 95% CI 1.7 to 3.5
SecondaryChange From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score

The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

Time frame:
Randomization (Week 36), Week 88
Reported as:
Least squares mean · score on a scale
Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score
score on a scalePlaceboTirzepatide MTD
Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score-5.0 ± 0.954.4 ± 0.91
Statistical analysis
  • Placebo vs Tirzepatide MTD · ANCOVA · p = <0.001 · Ls mean difference: 9.4 · 95% CI 6.8 to 12.0
SecondaryPercentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period

Percentage of Participants Who Maintain at least 80% of the Body Weight Lost During the Open-Label Lead-In Period was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.

Time frame:
Week 88
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period
percentage of participantsPlaceboTirzepatide MTD
Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period13.5093.37
Statistical analysis
  • Placebo vs Tirzepatide MTD · Regression, Logistic · p = <0.001 · Odds ratio (or): 95.91 · 95% CI 54.72 to 168.09
SecondaryPercentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline

Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction from baseline was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\*Time as variables.

Time frame:
Baseline (Week 0) to Week 88
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline
percentage of participantsPlaceboTirzepatide MTD
≥5% body weight reduction from baseline69.0098.49
≥10% body weight reduction from baseline44.3893.98
≥15% body weight reduction from baseline24.0187.05
≥20% body weight reduction from baseline11.5572.59
Statistical analysis
  • Placebo vs Tirzepatide MTD · Regression, Logistic · p = <0.001 · Odds ratio (or): 47.27 · 95% CI 18.32 to 121.99
  • Placebo vs Tirzepatide MTD · Regression, Logistic · p = <0.001 · Odds ratio (or): 71.51 · 95% CI 34.46 to 148.39
  • Placebo vs Tirzepatide MTD · Regression, Logistic · p = <0.001 · Odds ratio (or): 79.99 · 95% CI 42.06 to 152.14
  • Placebo vs Tirzepatide MTD · Regression, Logistic · p = <0.001 · Odds ratio (or): 140.84 · 95% CI 66.06 to 300.29
SecondaryTime to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period

Time to first occurrence of participants returning to \>95% baseline weight for those who lost ≥5% during the open-label lead-in period.

Time frame:
Randomization (Week 36) to Week 88
Reported as:
Median · weeks
Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period
weeksPlaceboTirzepatide MTD
Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In PeriodNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Placebo vs Tirzepatide MTD · Log Rank · p = <.001 · Hazard ratio (hr): 0.013 · 95% CI 0.004 to 0.046Unstratified hazard ratio from Cox proportional hazard model with Baseline Weight (kg), Analysis Country, Sex, IWRS MTD at Week 36, Weight at randomization (kg) as covariates.
SecondaryChange From Baseline in BMI

LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + BMI at randomization (kg/m\^2) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · kg/m^2
Change From Baseline in BMI
kg/m^2PlaceboTirzepatide MTD
Change From Baseline in BMI-3.6 ± 0.16-10.0 ± 0.15
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -6.4 · 95% CI -6.8 to -6.0
SecondaryChange From Baseline in Body Weight

LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight
kgPlaceboTirzepatide MTD
Change From Baseline in Body Weight-10.0 ± 0.43-27.6 ± 0.42
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -17.6 · 95% CI -18.8 to -16.4
SecondaryPercent Change From Baseline in Body Weight

LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight
percent changePlaceboTirzepatide MTD
Percent Change From Baseline in Body Weight-9.5 ± 0.40-26.0 ± 0.39
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -16.4 · 95% CI -17.5 to -15.4
SecondaryChange From Baseline in Waist Circumference

LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · cm
Change From Baseline in Waist Circumference
cmPlaceboTirzepatide MTD
Change From Baseline in Waist Circumference-9.1 ± 0.53-22.8 ± 0.52
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -13.6 · 95% CI -15.1 to -12.2
SecondaryChange From Baseline in Fasting Glucose

LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Glucose
mg/dLPlaceboTirzepatide MTD
Change From Baseline in Fasting Glucose-1.72 ± 0.543-10.63 ± 0.522
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -8.92 · 95% CI -10.40 to -7.43
SecondaryChange From Baseline in HbA1c

LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c
percentage of HbA1cPlaceboTirzepatide MTD
Change From Baseline in HbA1c-0.22 ± 0.018-0.57 ± 0.017
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -0.34 · 95% CI -0.39 to -0.29
SecondaryPercent Change From Baseline in Fasting Insulin

LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Fasting Insulin
percent changePlaceboTirzepatide MTD
Percent Change From Baseline in Fasting Insulin-29.8 ± 2.52-54.1 ± 1.57
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -34.6 · 95% CI -40.6 to -27.9
SecondaryPercent Change From Baseline in Lipid Parameters (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides, FFAs)

LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipid Parameters (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides, FFAs)
percent changePlaceboTirzepatide MTD
Total Cholesterol2.16 ± 0.919-5.01 ± 0.817
LDL Cholesterol2.62 ± 1.371-5.21 ± 1.207
HDL Cholesterol9.44 ± 1.09312.29 ± 1.071
VLDL Cholesterol-15.6 ± 1.82-32.6 ± 1.37
Triglycerides-15.3 ± 1.84-33.3 ± 1.38
FFA-9.69 ± 2.811-20.38 ± 2.360
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -7.02 · 95% CI -9.27 to -4.72
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -7.62 · 95% CI -10.91 to -4.21
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = 0.064 · Ls mean difference: 2.60 · 95% CI -0.14 to 5.43
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -20.1 · 95% CI -24.7 to -15.3
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -21.2 · 95% CI -25.8 to -16.4
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = 0.004 · Ls mean difference: -11.83 · 95% CI -18.98 to -4.06
SecondaryChange From Baseline in SBP, DBP

LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\< 10%, \>= 10%) + treatment + time + treatment\*time (Type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · mmHg
Change From Baseline in SBP, DBP
mmHgPlaceboTirzepatide MTD
SBP-2.4 ± 0.66-9.3 ± 0.63
DBP-1.7 ± 0.46-5.5 ± 0.44
Statistical analysis
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -6.9 · 95% CI -8.7 to -5.1
  • Placebo vs Tirzepatide MTD · Mixed Models Analysis · p = <.001 · Ls mean difference: -3.8 · 95% CI -5.1 to -2.6
SecondaryChange From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score

The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · T-score
Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score
T-scorePlaceboTirzepatide MTD
Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score3.7 ± 0.366.3 ± 0.34
Statistical analysis
  • Placebo vs Tirzepatide MTD · ANCOVA · p = <.001 · Ls mean difference: 2.7 · 95% CI 1.7 to 3.7
SecondaryChange From Baseline in IWQOL-Lite-CT - Physical Function Composite Score

The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was analysed by ANCOVA model with baseline + analysis Country + sex + weight loss at Week 36 (\< 10%, \>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.

Time frame:
Baseline (Week 0), Week 88
Reported as:
Least squares mean · score on a scale
Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score
score on a scalePlaceboTirzepatide MTD
Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score16.7 ± 1.0126.0 ± 0.97
Statistical analysis
  • Placebo vs Tirzepatide MTD · ANCOVA · p = <.001 · Ls mean difference: 9.3 · 95% CI 6.5 to 12.0

Adverse events

Collected over Week 0 to 36 for the open-label lead-in period arm, Week 36 to 92 for the double-blind study period arms.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide (lead-in)1/782 (0.1%)16/782 (2%)559/782 (71.5%)
Placebo1/335 (0.3%)10/335 (3%)100/335 (29.9%)
Tirzepatide MTD1/335 (0.3%)10/335 (3%)124/335 (37%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventTirzepatide (lead-in)PlaceboTirzepatide MTD
Cholecystitis acuteHepatobiliary disorders4/7823/3350/335
CellulitisInfections and infestations0/7820/3352/335
Acute myocardial infarctionCardiac disorders0/7820/3351/335
Cardiac failure congestiveCardiac disorders0/7820/3351/335
Abdominal painGastrointestinal disorders0/7820/3351/335
Intestinal obstructionGastrointestinal disorders0/7821/3351/335
NauseaGastrointestinal disorders0/7820/3351/335
Peptic ulcerGastrointestinal disorders0/7820/3351/335
Small intestinal obstructionGastrointestinal disorders0/7820/3351/335
VomitingGastrointestinal disorders0/7820/3351/335
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTirzepatide (lead-in)PlaceboTirzepatide MTD
NauseaGastrointestinal disorders278/7829/33527/335
DiarrhoeaGastrointestinal disorders165/78216/33536/335
ConstipationGastrointestinal disorders162/7828/33512/335
VomitingGastrointestinal disorders128/7824/33518/335
Covid-19Infections and infestations82/78250/33547/335
Decreased appetiteMetabolism and nutrition disorders74/7824/3357/335
Gastrooesophageal reflux diseaseGastrointestinal disorders69/7821/3354/335
Injection site reactionGeneral disorders64/7822/3357/335
DyspepsiaGastrointestinal disorders63/7821/3351/335
HeadacheNervous system disorders56/78210/3355/335

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboTirzepatide MTDTotal
Mean47.15 ± 12.3848.27 ± 12.7947.71 ± 12.59
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTirzepatide MTDTotal
Female237236473
Male9899197
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTirzepatide MTDTotal
Hispanic or Latino155141296
Not Hispanic or Latino180193373
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTirzepatide MTDTotal
American Indian or Alaska Native000
Asian222648
Native Hawaiian or Other Pacific Islander112
Black or African American363975
White273264537
More than one race358
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboTirzepatide MTDTotal
Argentina5655111
Brazil464389
Taiwan172138
United States216216432
Body weight
Body weight(kilogram (kg))PlaceboTirzepatide MTDTotal
Mean107.79 ± 23.66106.82 ± 20.94107.3 ± 22.33
08

Study locations

70 sites
  • Cahaba Research
    Pelham, Alabama 35124, United States
  • Scripps Memorial Hospital La Jolla
    La Jolla, California 92037, United States
  • National Research Institute - Wilshire
    Los Angeles, California 90057, United States
  • National Research Institute
    Panorama City, California 91402, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • New West Physicians Clinical Research
    Golden, Colorado 80401, United States
  • Optumcare Colorado Springs - Monument
    Monument, Colorado 80132, United States
  • Care Partners Clinical Research
    Jacksonville, Florida 32277, United States
  • South Florida Clinical Research Institute
    Margate, Florida 33063, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • SKY Clinical Research Network Group-Blake
    Union City, Georgia 30291, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Healthcare Research Network - Chicago
    Flossmoor, Illinois 60422, United States
  • Clinical Investigation Specialists
    Gurnee, Illinois 60031, United States
  • Midwest Institute For Clinical Research
    Indianapolis, Indiana 46260, United States
  • American Health Network of Indiana, LLC - New Albany
    New Albany, Indiana 47150, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Centennial Medical Group
    Elkridge, Maryland 21075, United States
  • MedStar Health Research Institute (MedStar Physician Based Research Network)
    Hyattsville, Maryland 20782, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Glacier View Research Institute - Endocrinology
    Kalispell, Montana 59901, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Wake Forest University Baptist Medical Center (WFUBMC)
    Winston-Salem, North Carolina 27157, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • The University of Texas Health Science Center at Houston
    Bellaire, Texas 77401, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • North Hills Family Medicine/North Hills Medical Research
    North Richland Hills, Texas 76180, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Northwest Houston Heart Center
    Tomball, Texas 77375, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
  • Capital Clinical Research Center
    Olympia, Washington 98502, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • CEDIC
    Caba, Buenos Aires C1060ABN, Argentina
  • Centro Médico Viamonte
    Caba, Buenos Aires C1120AAC, Argentina
  • Stat Research S.A.
    Ciudad Autónoma de Buenos Aire, Buenos Aires C1023AAB, Argentina
  • Mautalen Salud e Investigación
    Buenos Aires, Ciudad Autónoma De Buenos Aire C1128AAF, Argentina
  • Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada
    Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aire C1425AGC, Argentina
  • Instituto Médico Catamarca IMEC
    Rosario, Santa Fe 2000, Argentina
  • Asociación de Beneficencia Hospital Sirio Libanés
    Buenos Aires, C1419AHN, Argentina
  • CEDOES
    Vitória, Espírito Santo 29055450, Brazil
  • Cline Research Center
    Curitiba, Paraná 80030-480, Brazil
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul
    Porto Alegre, Rio Grande Do Sul 90430-001, Brazil
  • Centro de Pesquisa Sao Lucas
    Campinas, São Paulo 13034-685, Brazil
  • BR Trials - Ensaios Clinicos e Consultoria
    Sao Paulo, São Paulo 03325-050, Brazil
  • ISPEM - Instituto São José dos Campos em Pesquisas Médicas
    São José dos Campos, São Paulo 12243-280, Brazil
  • IBPClin - Instituto Brasil de Pesquisa Clínica
    Rio de Janeiro, 22241-180, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
  • Centro de Endocrinologia Alcantara Gonzalez
    Bayamon, 00959, Puerto Rico
  • Private Practice Dr. Martha Gomez Cuellar
    San Juan, 00921, Puerto Rico
  • Wellness clinical Research Vega Baja
    Vega Baja, 00694, Puerto Rico
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Cheng-Kung Uni. Hosp.
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Apr 2023, 24 months.

Results were first posted in May 2024, 1 year after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 9, 2020
StartActual
Mar 29, 2021
Primary completionActual
Apr 25, 2023
CompletionActual
May 18, 2023
Results first posted
May 22, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04660643
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Mar 29, 2021
Primary completion
Apr 25, 2023
Completion
May 18, 2023
Results posted
May 22, 2024
Last update
May 22, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion